As Losses Pile Up For Immunity Bio, Company Seeks FDA Approval For Drug
ImmunityBio officials are pictured at the 101st annual meeting of the South Central Section of the American Urological Association last fall. Anktiva, one of the company’s drugs that has been accepted for fast-track study by the federal Food and Drug Administration, is a treatment for muscle-invasive bladder cancer carcinoma.
Financial losses continue to pile up at ImmunityBio according to the company’s filing with the Securities and Exchange Commission on Thursday. The companies accumulated deficit…Business
US Home Sales Fade, Prices Hit All-Time High
Labor Department Proposes Workplace Rule Changes
Less Selection, Higher Prices
Do As I Say, Not As I Do: On My Failings As An Investor
If a knowledgeable observer trained his or her sights on my choices, what are the trouble spots they would ...
Walgreens Shareholders Approve $10 billion Private Equity Buyout
The Associated Press Shareholders of Walgreens Boots Alliance overwhelmingly approved the drugstore chain’s $10 ...
Retail Sales Up A Surprising 0.6% In June After A May Pullback By Consumers
WASHINGTON (AP) — After an earlier pullback, consumers picked up their spending in June despite anxiety over ...